NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.

Workspace · Cancer algorithms · Oral cavity and pharynx

Oral cavity and pharynx

Oral cavity and pharynx · 60,480 new · 13,150 deaths (ACS 2026) · mortality 2.7 per 100k · 5-yr RS 69.9% (SEER)

Mortality 2.7 per 100k (SEER / ACS common-sites). Never an artboard percent.

Lifetime ≈ 1.2% (SEER Stat Facts). 461,008 people living with oral cavity and pharynx cancer in 2023. No encoded screening interval.

461,008 people living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.

Median age at diagnosis 65 · at death 70 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.

Incidence men 17.5 / women 6.6 per 100k · mortality men 4.1 / women 1.4 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.

Most often diagnosed among people aged 65–74. Deaths highest among people aged 65–74. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.

New cases rising 1.0% each year (2014–2023). Death rates rising 0.8% each year (2015–2024). Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval.

Highest new-case rate: Non-Hispanic White men 20.9 per 100k. Highest death rate: Non-Hispanic White men 4.5 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

Race/ethnicity rates per 100k (SEER Stat Facts)

SEER Stat Facts race and ethnicity incidence and mortality per 100k
Group	Inc. men	Inc. women	Deaths men	Deaths women
Hispanic	10.5	4.8	2.4	0.8
Non-Hispanic American Indian/Alaska Native	17.8	7.6	3.7	1.8
Non-Hispanic Asian/Pacific Islander	12.1	5.9	3.1	1.2
Non-Hispanic Black	12.8	5.0	4.0	1.2
Non-Hispanic White	20.9	7.4	4.5	1.6

Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

USPSTF screening pointer

USPSTF 2013 I · Asymptomatic adults · Insufficient evidence — no population program

Cited only. No screening interval and no unpublished coefficient. USPSTF-oral-2013

ACS early-detection pointer

ACS 2026 · People without oral or oropharyngeal symptoms · ACS (2026): in the United States, doctors do not recommend routine screening for oral cavity and oropharyngeal cancers. There are no simple exams or blood tests that can find these cancers early, and there is no approved test to screen for HPV in the throat. Dental and self exams are named as ways some cancers are found; they are not a population visual-screen program. Complementary to the cited USPSTF 2013 I statement. Not an oral visual-screen or throat-HPV engine.

Cited ACS statement only. Not a screening engine. ACS-oral-detect

USPSTF counseling pointer

USPSTF 2021 A/I · Adults 18 years or older, including pregnant persons · USPSTF 2021 tobacco-cessation statement (Grade A/I) is about asking, advising, and offering proven cessation help — not an oral-cancer visual-screen program. Complementary to the cited 2013 I statement. Not equivalent. No 5 A's engine is encoded.

Cited tobacco-cessation statement only. Not an oral-cancer visual-screen program. USPSTF-tobacco-2021

USPSTF counseling pointer

USPSTF 2020 B/I · School-aged children and adolescents younger than 18 · USPSTF 2020 youth tobacco-prevention statement (Grade B/I) is about preventing initiation and the insufficient evidence for youth cessation — not an oral-cancer visual-screen program. Complementary to the cited 2021 adult cessation statement and the 2013 I oral-screening statement. Not equivalent. No youth 5 A's or school-counseling engine. Official evidence-review percents from that page are not restated.

Cited youth tobacco-prevention statement only. Not an oral-cancer visual-screen program. USPSTF-youth-tobacco-2020

Surveillance pointer

ACS-oral-follow 2026 · cited only · ACS after-treatment page names physical exams and endoscopy on a typical cadence after oral-cavity or oropharyngeal treatment. Those months are not encoded. Not an oral visual-screen or throat-HPV engine.

Named public source only. Not a personal follow-up calendar. ACS-oral-follow

Surveillance pointer

ACS-oral-follow 2026 · cited only · ACS after-treatment page names second cancers after oral cavity and oropharyngeal treatment. Named later-cancer sites are not encoded. Complementary to the living-as pointer. Not an oral visual-screen or throat-HPV engine. Not a second-primary screening engine.

Named public source only. Not a personal follow-up calendar. ACS-oral-follow

Surveillance pointer

ACS-long-term-effects 2025 · cited only · ACS long-term page names a dentist at least once every 6 months after treatments that raise cavity and tooth-loss risk, plus thyroid checks every so often after head-and-neck treatment, and hearing or vision change after head radiation. Those intervals are named, not encoded. Complementary to the living-as pointer. Official lifetime figures are not restated. Not a dental-calendar, thyroid-lab, or audiogram engine.

Named public source only. Not a personal follow-up calendar. ACS-long-term-effects

Surveillance pointer

ACS-follow-up-care 2025 · cited only · ACS follow-up-care page names a yearly thyroid exam after radiation to the head, neck, or throat, plus a treatment summary and survivorship care plan. Those named tests and plans are not encoded. Complementary to the head-and-neck printout. Official lifetime figures are not restated. Not a dental-calendar, thyroid-lab, or oral visual-screen engine.

Named public source only. Not a personal follow-up calendar. ACS-follow-up-care

Toxicity pointer

ACS-oral-follow 2026 · empty on purpose · ACS after-treatment page names long-term treatment side effects after oral-cavity or oropharyngeal care. Those late effects are not encoded. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-oral-follow

Toxicity pointer

ACS-oral-follow 2026 · empty on purpose · ACS after-treatment page names later cancers after oral cavity and oropharyngeal treatment. Those second-cancer risks are not encoded. Complementary to the living-as pointer. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-oral-follow

Toxicity pointer

ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later hypothyroidism after head-and-neck radiation, osteonecrosis of the jaw after jaw radiation or bisphosphonates, hearing loss after platinum or head radiation, and lymphedema after neck-node treatment. Those late effects are not encoded. Official lifetime figures are not restated. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-long-term-effects

Toxicity pointer

ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names a yearly thyroid exam after head, neck, or throat radiation. That named test is not encoded. Official lifetime figures are not restated. Complementary to the head-and-neck printout. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-follow-up-care

Late toxicity printout

Late toxicity printout — Head and neck

Acute: ACS names fatigue, mouth or throat sores, dry mouth, swallowing trouble, nausea, earaches, and swelling. Late: lasting dry mouth, tooth decay, jaw stiffness, thyroid problems, jaw osteonecrosis, lymphedema, hearing or vision change, and lasting fatigue. Monitor: dental check before RT; a dentist at least once every 6 months after cavity-risk treatment; yearly thyroid exam after head, neck, or throat radiation; lasting fatigue or sleep problems. Those names are not encoded. Official lifetime figures are not restated. Not a dental-calendar, thyroid-lab, or oral visual-screen engine.

Questions to ask

ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.

ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.

ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.

Treatment summary and care plan

ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.

How late effects are managed

ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.

ACS long-term late names

Lymphedema after neck-node surgery or RT
Hearing loss after head RT or platinum chemo
Vision change after head or eye RT
Cancer-related fatigue that lasts
Joint or muscle pain after some treatments
Mental health and distress after treatment
Low thyroid hormones after head or neck radiation
Lymphedema after lymph-node surgery or radiation

ACS follow-up tests named here

Yearly thyroid exam after head, neck, or throat radiation

Named conditions to monitor

Mouth care and dental check before RT
Ongoing dry mouth and cavities
Thyroid after neck RT
Dental visits after head-and-neck treatment
Cancer-related fatigue or sleep problems that last
Joint or muscle pain after chemo, steroids, or hormone therapy
Anxiety, depression, or fear of recurrence after treatment
Fatigue, hair loss, or feeling colder after head or neck radiation
New swelling after lymph-node surgery or radiation
Second-cancer awareness after radiation or chemo
Ask which late-effect tests belong on the follow-up plan

Acute toxicities · Late toxicities · Named conditions to monitor. Cadences are placeholders. Named tests are not encoded. Cited ACS head-and-neck names only. Complementary ACS long-term page is named, not encoded. Not a dysphagia-score or dental-interval engine. Official lifetime-risk figures are not restated. No invented trial percent.

Open Head and neck printout →

NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.

algo-stub-oral · stub · none · v2-stub-oral

SEER 5-year relative survival by stage (cited stub)

Localized 88.7% · Regional 69.7% · Distant 36.0% · All 69.9%

Oral cavity and pharynx. No encoded screening interval.

Percent of cases by stage (SEER Stat Facts)

Localized 26% · Regional 55% · Distant 12% · Unknown 6%

Percent of cases at diagnosis — not 5-year relative survival. SEER Combined Summary Stage.

lifetime
Oral cavity and pharynx birth-to-death
≈ 1.2%

Screening · Surveillance · Toxicity on four golden fixtures

Rio · Plan — survivor

not computed — v2 stub

Cited ACS/SEER population pin only

screening
USPSTF 2013 I — insufficient evidence for a visual-screen program
Cited USPSTF 2013 I and ACS 2026 no-routine-screen note. Dental and self exams are not a population visual-screen program.
not encoded
surveillance
ACS follow-up cited — oral months not encoded
Cited ACS after-treatment page only. Not an oral visual-screen or throat-HPV engine.
not encoded
toxicity
ACS late effects cited — oral months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Noah · Plan — skin cancer

not computed — v2 stub

Cited ACS/SEER population pin only

screening
USPSTF 2013 I — insufficient evidence for a visual-screen program
Cited USPSTF 2013 I and ACS 2026 no-routine-screen note. Dental and self exams are not a population visual-screen program.
not encoded
surveillance
ACS follow-up cited — oral months not encoded
Cited ACS after-treatment page only. Not an oral visual-screen or throat-HPV engine.
not encoded
toxicity
ACS late effects cited — oral months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Walter · S1 prostate

not computed — v2 stub

Cited ACS/SEER population pin only

screening
USPSTF 2013 I — insufficient evidence for a visual-screen program
Cited USPSTF 2013 I and ACS 2026 no-routine-screen note. Dental and self exams are not a population visual-screen program.
not encoded
surveillance
ACS follow-up cited — oral months not encoded
Cited ACS after-treatment page only. Not an oral visual-screen or throat-HPV engine.
not encoded
toxicity
ACS late effects cited — oral months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Priya · average-risk

not computed — v2 stub

Cited ACS/SEER population pin only

screening
USPSTF 2013 I — insufficient evidence for a visual-screen program
Cited USPSTF 2013 I and ACS 2026 no-routine-screen note. Dental and self exams are not a population visual-screen program.
not encoded
surveillance
ACS follow-up cited — oral months not encoded
Cited ACS after-treatment page only. Not an oral visual-screen or throat-HPV engine.
not encoded
toxicity
ACS late effects cited — oral months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Not implemented. Cited public snapshot only. Not a screening recommendation. Mortality is a rate per 100k, not an artboard percent.

All cancers →Screening →Surveillance →Toxicity →